<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608800</url>
  </required_header>
  <id_info>
    <org_study_id>2018IF01-1</org_study_id>
    <nct_id>NCT03608800</nct_id>
  </id_info>
  <brief_title>Potential Effects of Intermittent Fasting to Metabolic Syndrome</brief_title>
  <official_title>Potential Effects of Intermittent Fasting to Gut Microbiota of Metabolic Syndrome Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Min Xia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The survey is designed to investigate whether 8 weeks of discrete two-day intermittent
      fasting per week will impact gut microbiota and cardiovascular risks of metabolic syndrome
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent fasting was demonstrated to optimize energy metabolism and promote health.
      However, the benefits of intermittent fasting to gut microbiota are remain unclear. Further
      evidence is needed in understanding the effects of intermittent fasting to gut microbiota and
      cardiovascular risks in subjects with metabolic syndrome
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2018</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>8 weeks</time_frame>
    <description>BMI(weight in kilograms, height in meters and BMI in kg/m^2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body fat mass</measure>
    <time_frame>8 weeks</time_frame>
    <description>Body fat mass (kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>systolic pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>systolic pressure(mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>diastolic pressure(mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut microbiota composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>gut microbiota composition at different levels of classification determined by 16s rRNA pcr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma IL-6</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma interleukin 6 (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma TNF-α</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma TNF-α (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma sCD40L</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma soluble CD40 ligand (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma leptin</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma leptin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma adiponectin</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma adiponectin (μg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma MDA</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma malondialdehyde (nmol/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma oxLDL</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma oxidative LDL (mU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma total nitrate</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma total nitrate (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma AMDA</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma asymmetric dimethylarginine (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma VCAM-1</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma vascular cell adhesion protein 1 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma vWF</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma Von Willebrand factor (U/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic pathway of gut microbiota</measure>
    <time_frame>8 weeks</time_frame>
    <description>metabolic pathway of gut microbiota determined by 16s rRNA pcr</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum LDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum LDL-cholesterol(mmol/L);</description>
  </other_outcome>
  <other_outcome>
    <measure>serum HDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum HDL-cholesterol (mmol/L);</description>
  </other_outcome>
  <other_outcome>
    <measure>serum triglyceride</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum triglyceride (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>serum Apo B/apo A1</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum Apo B/apo A1</description>
  </other_outcome>
  <other_outcome>
    <measure>serum glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum glucose (mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>serum insulin</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum insulin (mU/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>serum total cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum total cholesterol (mmol/L)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Intermittent fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two nonconsecutive days of 75% diet energy restriction per week for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>maintain the energy intake as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intermittent fasting</intervention_name>
    <description>The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks</description>
    <arm_group_label>Intermittent fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Local residents aged between 30 to 50 years old

          -  Stable body weight (change &lt;±10% of body weight) for 3 months before the study

          -  Central obesity: waist circumference ≥90 cm in males or ≥80 cm in females; plus any
             two of the following four conditions:

               1. Elevated triglycerides: serum triglycerides ≥150 mg/dL (1.7 mmol/L)

               2. Reduced HDL cholesterol: serum HDL-c &lt;40 mg/dL (1.03 mmol/L) in males or &lt;50
                  mg/dL (1.29 mmol/L) in females

               3. Elevated blood pressure: systolic blood pressure ≥130 mmHg or diastolic blood
                  pressure ≥85 mmHg or receiving medication of hypertension

               4. Elevated fasting plasma glucose: fasting plasma glucose ≥100 mg/dL (5.6 mmol/L)

        Exclusion Criteria:

          -  History of cardiovascular and cerebrovascular diseases

          -  Acute or chronic infectious diseases within 4 weeks

          -  Known malignant tumor

          -  Alcohol abuse (weekly consumption of alcohol is more than 70 g in females or 140 g in
             males)

          -  Regular therapy with antihypertensive drug, hypolipidemic agents, hypoglycemic agents,
             hormonal agents and antidepressants within 6 months

          -  Use of probiotics, prebiotics or antibiotics within 3 months and in progress of study

          -  Use of antiinflammatory drug in progress of study

          -  Following a vegetarian diet or veganism

          -  Women who are pregnant or intend to be pregnant during the research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Xia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nutrition and Food Hygiene</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Min Xia</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

